Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
INMD vs DCTH: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
INMD Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 8–2 Matrix Metrics)
INMD Overall Winner
6-Pillar Tally: INMD 3 – 3 DCTH
Matrix Metrics: INMD 8 – 2 DCTH
As of Nov 16, 2026, InMode Ltd. (INMD) is the stronger overall head-to-head candidate over Delcath Systems Inc (DCTH) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). INMD carries a Unified Composite Score of 50.5/100 (HOLD) at $13.12 (9.8x Forward P/E, 17.6% operating margin), whereas DCTH carries 35.9/100 (SELL) at $19.68 (N/M Forward P/E, 5.2% operating margin).
- Growth vs. Quality Trade-Off: INMD earns the overall head-to-head edge with a stronger Unified Composite Score (50.5/100 HOLD vs. DCTH 35.9/100 SELL) and 0.59β · 35% Vol risk profile, whereas DCTH leads top-line expansion (+70.7% YoY revenue growth, 1.60x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
- Technical & Structure Timing Caution: INMD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.1); meanwhile DCTH trades in a Neutral technical trend (BREAKOUT options phase, RSI 68.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About INMD vs DCTH
INMD
Head-to-Head Winner
InMode Ltd. Ordinary Shares
$13.12
-1.09% 1D
Market Cap
$759.0M
TTM Revenue
$374M
Forward P/E
9.8x
Beta / 30D Vol
0.59β · 35% Vol
Unified Composite Score
50.5
HOLD
Tech 41.0
Fund 54.0
Flow 70.0
Mom 50.0
Weinstein Technical Phase
Markdown · Sell / avoid
DCTH
Delcath Systems Inc
$19.68
-4.23% 1D
Market Cap
$743.8M
TTM Revenue
$110M
Forward P/E
N/M
Beta / 30D Vol
1.63β · 131% Vol
Unified Composite Score
35.9
SELL
Tech 50.0
Fund 38.0
Flow 60.0
Mom 54.0
Weinstein Technical Phase
Neutral · Hold
6-Pillar Scorecard Institutional Category Breakdown (INMD 3 – 3 DCTH)
1. Valuation Multiples
INMD
Forward P/E
9.8x
N/M
Trailing P/E
10.9x
133.6x
PEG Ratio
2.90x
1.60x
EV / Revenue
1.0x
6.3x
2. Growth & Scale
DCTH
Revenue Growth (YoY)
-1.1%
+70.7%
Earnings Growth (YoY)
-5.9%
+750.0%
TTM Revenue (USD)
$374M
$110M
Market Cap
$759.0M
$743.8M
3. Profitability & Quality
INMD
Gross Margin
76.6%
87.6%
Operating Margin
17.6%
5.2%
Net Profit Margin
20.0%
6.0%
Return on Equity (ROE)
11.4%
5.4%
4. Balance Sheet & Cash Flow
INMD
Cash Generation (TTM)
$69M
$20M
Cash Flow Margin
18.6%
18.3%
Net Cash / Leverage
$394M Net Cash
$53M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
DCTH
Options Structure Phase
CONSOLIDATION
BREAKOUT
Current IV / %ile
36.5% (9th %ile)
109.3% (43rd %ile)
Put/Call OI Skew
0.74x (Call-Skewed)
0.11x (Call-Skewed)
OBV Trend / Tech Phase
DISTRIBUTION · Markdown
ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat
DCTH
OpEx & R&D Intensity
59.0% of Rev ($220M)
82.4% of Rev ($91M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Scale & Operating Efficiency Moat
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Medical Devices Operator
Medical Devices Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: INMD (8) vs DCTH (2)| Institutional Metric | INMD | DCTH | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $759.0M | $743.8M | INMD | |
| Trailing P/E Ratio | 10.9x | 133.6x | INMD | |
| Forward P/E Ratio | 9.8x | N/M | INMD | |
| Revenue Growth (YoY) | -1.1% | +70.7% | DCTH | |
| Operating Margin (TTM) | 17.6% | 5.2% | INMD | |
| Net Profit Margin | 20.0% | 6.0% | INMD | |
| Return on Equity (ROE) | 11.4% | 5.4% | INMD | |
| 52-Week Range Position | 10% ($13–$17) | 80% ($8–$23) | DCTH | |
| Beta / 30D Volatility | 0.59β · 35% Vol | 1.63β · 131% Vol | INMD | |
| Unified Institutional Score | 50.5 / 100 (HOLD) | 35.9 / 100 (SELL) | INMD | |
| Trailing 12M Revenue (USD) | $374M | $110M | Scale | |
| Gross Profit Margin (TTM) | 76.6% | 87.6% | Quality | |
| PEG Ratio & EV / Revenue | 2.90x PEG · 1.0x EV/Rev | 1.60x PEG · 6.3x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | $69M ($394M Net Cash) | $20M ($53M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
DCTH +47.08 pp
3M Horizon
DCTH +29.17 pp
6M Horizon
DCTH +84.37 pp
1Y Horizon
DCTH +136.79 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | INMD Revenue | DCTH Revenue | INMD Op. Margin | DCTH Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $100M | N/A | 23.5% | N/A | INMD |
| FY2019 | $160M | N/A | 38.1% | N/A | INMD |
| FY2020 | $210M | N/A | 35.3% | N/A | INMD |
| FY2021 | $360M | $0M | 46.8% | -690.0% | INMD |
| FY2022 | $450M | $0M | 43.6% | -1245.1% | INMD |
| FY2023 | $490M | $0M | 39.8% | -1849.0% | INMD |
| FY2024 | $390M | $40M | 28.5% | -33.4% | INMD |
| FY2025 | $370M | $90M | 23.0% | 0.8% | INMD |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
INMD
CONSOLIDATION
Current IV
36.5%
IV Percentile
9th %ile
Put/Call OI Skew
0.74x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BEARISH
OBV Flow
DISTRIBUTION
Exact INMD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
DCTH
BREAKOUT
Current IV
109.3%
IV Percentile
43rd %ile
Put/Call OI Skew
0.11x (Call-Skewed)
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
ACCUMULATION
Exact DCTH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
INMD Moat Profile
Scale & Operating Efficiency Moat
Medical Devices Operator
OpEx & R&D Reinvestment
59.0% of Rev ($220M)
90D Engineering Disclosures
0 Published
DCTH Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
82.4% of Rev ($91M)
90D Engineering Disclosures
0 Published
Investor FAQ INMD vs DCTH Key Questions & Quantitative Answers
As of Nov 16, 2026, InMode Ltd. (INMD) is the stronger overall head-to-head candidate over Delcath Systems Inc (DCTH) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). INMD carries a Unified Composite Score of 50.5/100 (HOLD) at $13.12 (9.8x Forward P/E, 17.6% operating margin), whereas DCTH carries 35.9/100 (SELL) at $19.68 (N/M Forward P/E, 5.2% operating margin). Growth vs. Quality Trade-Off: INMD earns the overall head-to-head edge with a stronger Unified Composite Score (50.5/100 HOLD vs. DCTH 35.9/100 SELL) and 0.59β · 35% Vol risk profile, whereas DCTH leads top-line expansion (+70.7% YoY revenue growth, 1.60x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: INMD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.1); meanwhile DCTH trades in a Neutral technical trend (BREAKOUT options phase, RSI 68.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
DCTH leads the Growth & Scale pillar: INMD posts -1.1% YoY revenue growth and -5.9% YoY earnings growth on $374M TTM revenue (76.6% gross margin, 17.6% operating margin), compared with DCTH at +70.7% YoY revenue growth and +750.0% YoY earnings growth on $110M TTM revenue (87.6% gross margin, 5.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), INMD cumulative revenue shifted +270.0% while DCTH shifted +125.0%. In operating R&D and SG&A reinvestment, INMD deploys 59.0% of Rev ($220M) (0 90-day corporate R&D disclosures) versus 82.4% of Rev ($91M) (0 disclosures) for DCTH.
INMD screens cheaper on headline valuation multiples. INMD trades at 9.8x Forward P/E, 10.9x Trailing P/E, 2.90x PEG, and 1.0x EV/Revenue (18.6% FCF margin), whereas DCTH trades at N/M Forward P/E, 133.6x Trailing P/E, 1.60x PEG, and 6.3x EV/Revenue (18.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against INMD (11.4% ROE) versus DCTH (5.4% ROE) capital efficiency.
In options market volatility and institutional positioning, INMD carries 36.5% implied volatility (9th %ile, Compressed (<25th %ile)), a 0.74x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.59β · 35% Vol realized risk). By comparison, DCTH carries 109.3% implied volatility (43rd %ile, Balanced (25th–60th %ile)), a 0.11x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.63β · 131% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
DCTH vs INMD · Reverse Pair
INMD vs PGNY
· Sector Peer
INMD vs DOCS
· Sector Peer
INMD vs APPS
· Sector Peer
DCTH vs CRMD
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma